 Biogen Idec Inc reported positive interim results from an earlystage study of an Alzheimers disease drug sending the companys shares higher and renewing debate about drugs that attack amyloid plaques in the brain The study which is still under way is testing Biogens drug against a placebo in  patients with early forms of Alzheimers Interim results showed the drug reduced beta amyloid levels in the brain and had a statistically significant effect on cognition after  weeks of treatment Biogens research and
  